МЕК как терапевтическая мишень в онкологии
Аннотация
Протеины подсемейства МЕК, и в частности МЕК 1/2 являются одними из ключевых в карциногенезе. Рассмотрен механизм действия МЕК ингибиторов. Приведены результаты ряда современных клинических исследований с использованием МЕК ингибиторов, представлены данные их эффективности и токсичности. В обсуждении автором всесторонне проанализированы возможные причины их низкой эффективности у больных с различной онкопатологией, в том числе и с учетом наличия мутаций BRAF, KRAS, NRAS. Рассмотрены перспективы решения этой проблемы, также обоснован мультимодальный подход с использованием комбинированной таргетной терапии и цитостатиков. Сокращения: НМРК – немелкоклеточный рак легкого, МАРК – митогенактивированные протеин киназы, FDA(Food and Drug Administration) – Управление по санитарному надзору за качеством пищевых продуктов и медикаментов, ЦНС – центральная нервная система.
Об авторе
Любовь Юрьевна Владимирова
ФГБУ «Ростовский научно-исследовательский онкологический институт» Минздрава России
Россия
г. Ростов-на-Дону
Россия
г. Ростов-на-Дону
Список литературы
1. Владимирова Л. Ю. Применение ингибиторов МЕК в онкологии: результаты и перспективы // Успехи современного естествознания. – 2015. – № 3.– С. 18–30.
2. Adjei A. A., Cohen R. B., Franklin W., et.al. 2008. Phase I pharmacokinetic and pharmodynamic study of the oral, smallmolecule mitogen-activated protein kinase kinase1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 26(13), 2139–2146. PMID: 18390968. Epub 2008 Apr 7.
3. Ahmed S. R., Azad N. S., Ball D. W., A, et.al. 48th Annual Meeting of the American Society of Clinical Oncology.2012. Chicago, USA. Suppl. J. Clin. Oncology. 30(15S).P.202s. AbstractTPS3117.
4. Akinleye A., Furqan M., Mukhi N. et al.2013. MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol.6,27.
5. Banerji U., Camidge D. R., Verheul H. M., et.al. 2010. The fistin-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 16(5), 1613–1623. PMID: 20179232. Epub 2010 Feb 23.
6. Bardelli A. 50th Annual Meeting of the American Society of Clinical Oncology.2014. Chicago, USA. Suppl. J. Clin. Oncology. 32(15S).P.173 s. Abstract 2626.
7. Becerra C., Infante J. R., Gardo L. E. et.al. 49th Annual Meeting of the American Society of Clinical Oncology.2013. Chicago, USA. Suppl. J. Clin. Oncology. 30(15S).P.178s.Abstract 3023.
8. Bekaii-Saab T., Phelps M. A., Li X. et al. 2011 Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol., 29(17, 2357–2363. PMID: 21519026. Epub 2001 Apr 25.
9. Bennouna J., Lang I., Valladares- Ayerbes M. et.al. 2011.A Phase II, open-label, randomized study to assess the efficacy and safety of the MEK 1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs.; 29(5),1021–1028. PMID: 20127139. Epub 2010 Feb2.
10. Bodoky G., Timcheva C., Spigel D. R. et.al. 2012A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 (ARRY-14286)) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs. 30(3), 1216–1223. PMID: 21594619. Epub 2011 May 19.
11. Catalanotti F., Solit D. B., Pulitzer M. P., et al. 2013 Phase II trial of MEK inhibitor selumetinib (AZD6244) in patients with BRAFV600E/K- mutated melanoma. Clin Cancer Res.. PMID: 23444215. Epub 2013 Feb 26.
12. Cowley S., Paterson H., Kemp P., et al., Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3Т 3 cells. 1994.Cell. 77(6), 841–852. PMID: 7911739.
13. Delord J., Houede N., Awada A.et.al. First-in-human phase a safety pharmacokinetic (PK) and pharmacodynamics (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens (R)) in patients (pts) with advanced solid tumors. J. Clin Oncol. 2010; 28(15s) Abstract 2504.
14. Deming DA, Schelman WR, Lubner SJ, et.al. 48th Annual Meeting of the American Society of Clinical Oncology.2012. Chicago, USA. Suppl. J. Clin. Oncology. 32(15S),198s.Abstract 3103.
15. Drosten M., Dhawahir A., Sum E. Y., et al.2010 Genetic analysis of Ras signaling pathways in cell proliferation, migration and survival.EMBO J. 29,1091–1104.
16. Falchook G. S., Lewis K. D., Infante J. R. et al. 2012.Activity of the oral MEK inhibitor tramrtinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13(8), 782–789. PMID: 22805292. Epub 2012 Jul 16.
17. Ferguson J., Arozarena I., Ehrhardt M.et al. 2013.Combination of MEK and SRC inhibition suppresses melanoma cell growth and invasion. Oncogene. 32(1), 86–96.
18. Flaherty J. R., Robert C., Hersey P. et.al. 2012. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med; 367(2), 107–114. PMID: 22663011. Epub 2012 Jun 4.
19. Friday B. B., Yu C., Dy G. K. et.al. 2008. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res. 68(15),6145–6153. PMID: 128676837.
20. Gogas H. 50th Annual Meeting of the American Society of Clinical Oncology.2014. Chicago, USA. Suppl. J. Clin. Oncology. 32(15S).P.586 s.Abstract 9061.
21. Hainsworth J. D., Cebotaru C. L., Kanarev V. et.al. 2010.A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol., 5(10,1630–1636. PMID: 20802351.
22. Hatzivassiliou G., Haling J. R., Chen H., et al.2013. Mechanism of MEK inhibition determines efficacy in mutant KRAS-versus BRAF-driven cancers. Nature. 501,232–236.
23. Hayes D. N., Lucas A. S., Tanvetyanon T., et.al. 2012.Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 18(7), 2056–2065. PMID: 22241789. Epub 2012 Jan 12.
24. Hoshino R., Chatani Y., Yamori T., et al. 1999. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 18(3), 813–822. PMID: 9989833.
25. Houede N., Faivre S. J., Awada A. et al. 2011. 47th Annual Meeting of the American Society of Clinical Oncology. 2011. Chicago, USA. Suppl. J. Clin. Oncology. 29(15S).P.198s. Abstract 3019.
26. Hu-Lieskovan S. 50th Annual Meeting of the American Society of Clinical Oncology.2014. Chicago, USA. Suppl. J. Clin. Oncology. 32(15S).P.145s.Abstract 2512.
27. Infante J. R., Fecher L. A., Falchook G. S. 2012. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol.13(8),773–781.
28. Infante J. R., Patnaik A., Jonea S. F.P. et.al.2011. A phase
29. IB study of the MEK inhibitor GSK 1120212 combined with everolimus in patients with solid tumors: Interim results. MolCancer Ther. 10(11s), Abstract B128.
30. Infante J. R., Somer B. G., Park J. O. et.al.2013. A randomized, double-blind, placebo-controlled trial of tramrtinib, a MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas. J Clin Oncol. 31(4s). Abstract 291.
31. Janne P. A., Shaw A. T., Pereira J. R. et al.2013. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer; a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 14,38–47.
32. Khurum Hayat L. Y., Mezynski J., Patnaik A., et.al. 2012.A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK1/2 inhibitor) in patients with advanced or metastatic solid tumors. J Clin Oncol.; 30 (15s): e13599.
33. Kim K. B., Kefford R., Pavlick A. C.et.al.2013.. Phase II Study of the MEK 1/MEK2 inhibitor Trametinib in Patients with metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated with or without a BRAF inhibitor. J Clin Oncol.31(4), 482–489.PMID: 23248257. Epub 2012 Dec17.
34. Kirkwood J. M., Bastholt L., Robert C. et.al. 2012. A phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolamide in patients with advanced melanoma. Clin Cancer Res.18(2): 555–567. PMID: 22048237. Epub 2011 Nov 2.
35. Kohno M., Tanimura S., Ozaki K., et al.2011. Targeting the extracellular signal-regulated kinase pathway in cancer therapy. Biol.Pharm.Bull.34,1781–1784.
36. Kolch W., Heidecker G., Lloyd P., et al. 1991Raf-1 protein kinase is required for growth of induced NIH/ 3Т 3 cells. Nature. 349 (6308), 426–428. PMID: 1992343.
37. Kurzokh R., Patnaik A., Rosenstein L. et.al. 2011. 47th Annual Meeting of the American Society of Clinical Oncology.2011. Chicago, USA. Suppl. J. Clin. Oncology. 29(15S).P.215s. Abstract 3085.
38. Lee L., Niu H., Rueger R., et al.2009.The safety, tolerability, pharmacokinetics< and pharmacodynamics of single oral doses of CH 4987655 in healthy volunteers: target suppression using a biomarker. Clin.Cancer Res.15(23),7368–7374.
39. Liu S., Kurzrock R. 2014. Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. Cancer Treatment Reviews,40(7), 883–89.
40. Long G. V. 50th Annual Meeting of the American Society of Clinical Oncology.2014. Chicago, USA. Suppl. J. Clin. Oncology. 32(15S).P.574s. Abstract 9011.
41. LoRusso P.M., Adjeji A. A., Varterasian M., et.al. 2005.Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol. 23(23),5281–5293. PMID: 16009947. Epub 2005 Jul 11.
42. LoRusso P.M., Krishnamurthi S. S., Rinehart J. J. et al. 2010. Phase I pharmacokinetic and pharmacodynamics study of the oral MAPK/ ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res. 16(6), 1924–1937. PMID: 20215549. Epub 2010 Mar 9.
43. Macarulla T, Cervantes A, Rosello S, et.al. 2012.Phase I/II study of folfiri plus the MEK 1/2 inhibitor pimasrtib (msc1936369b) as second-line treatment for KRAS mutated metastaic colorectal cancer. Ann Oncol.23 (suppl 4): iv19-iv 30.
44. Marshall C. J. 1996.Cell signaling. Raf gets it together. Nature. 383(6596), 127–128. PMID8774875.
45. McArthur G.A. 2012. The coming age of MEK. Lancet Oncology.13(8),744–745.
46. Meier F. E. 50th Annual Meeting of the American Society of Clinical Oncology.2014. Chicago, USA. Suppl. J. Clin. Oncology. 32(15S).P.587s.Abstract 9062.
47. Miller C. R., Oliver K. E., Farley J. H. 2014.MEK1/2 inhibitors in the treatment of gynecologic malignancies. Gynecologic Oncology.133(1),128–137.
48. Moodie S. A., Willumsen B. M., Weber M. J., et.al. 1993. Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. Science.; 260 (5114), 1658–1661. PMID: 8503013.
49. Nitin Jain Curren E., Iyengar N. M. et al. 48th Annual Meeting of the American Society of Clinical Oncology.2012. Chicago, USA. Suppl. J. Clin. Oncology. 32(15S).P.436s.Abstract6582.
50. O’Neil B.N., Goff L. W., Kauh J. S., et.al. 2011. Phase II study of the mitogen-activated protein kinase1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 29(17), 2350–2356. PMID: 21519015. Epub 2011 Apr 25.
51. Ohren J. F., Chen H., Pavlovsky A., et al. 2004. Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol. Biol. 11(12),1192–1197. PMID: 15543157. Epub 2004 Nov 14.
52. Roskoski R Jr. 2012. ERK 1/2 MAP kinases: structure, function and regulation. Pharmacol. Res.; 66(2),105–143. PMID: 22569528. Epub 2012 Apr 27.
53. Solit d.B., Garraway L. A., Pratilas C. A., et al.2006.BRAF mutation predicts sensitivity to MEK inhibition. Nature.439,358–362.
54. Spreafico A., Tentler J. J., Pitts T. M. 2013. Rational combination of MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporine A, in preclinical models of colorectal cancer. Clin.Cancer Res. 19(15), 4149–4162.
55. Stefanofsky V. Y., Pelletier G., Hannan R., et. al. 2001.An immediate response of ribosomal transcription to- growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol Cell. 8(5), 1063–1073. PMID: 11741541.
56. Trujillo J.l. 2011.MEK inhibitors: a patent review2008–2010. Expert Opin Ther Pat. 21(7),1045–1069. PMID: 15543157. Epub 2011 May 9.
57. Wasylyk B., Hagman J., and Gutierrez-Hartmann A. Ets transcription factors, nuclear effectors of the Ras-MAP-kinase signaling pathway. 1998.Trends Biochem Sci. 23(6), 213–216. PMID: 9644975.
58. Weinstein-Oppenheimer C.R., Blalock W. L., Steelman L. S., et. al. 2000.The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther.88(3),229–279. PMID: 11337027.
59. Wong H., Vernillet L., Peterson A., et al. 2012. Briging the gap between preclinical and clinical studies using pharmacokineticpharmacodynamic modeling: an analysis of GDC-0973, a MEK inhibitor. Clin.Cancer Res.18,3090–3099.
60. Yamaguchi T., Kakefuda R., Tajima N., et al. 2011. Antitumor activities of JTP-74057(GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int. J. Oncol. 39,23–31.
61. Zhang J. 50th Annual Meeting of the American Society of Clinical Oncology.2014. Chicago, USA. Suppl. J. Clin. Oncology. 32(15S).P.164s.Abstract 2589.
Рецензия
Для цитирования:
Владимирова Л.Ю. МЕК как терапевтическая мишень в онкологии. Злокачественные опухоли. 2015;(4s2):20-27.
Просмотров:
870
Послать статью по эл. почте 